文献速递新发突发、热带与寄生虫病

间日疟化学预防:阿托伐醌-氯胍与其他方案的作用比较

Vivax Malaria Chemoprophylaxis: The Role of Atovaquone-Proguanil Compared to Other Options.
PubMed 文献 · Clin Infect Dis · 2018-01-01

回顾性观察研究纳入252名曾赴埃塞俄比亚奥莫河高疟区的以色列漂流者,随访至少1年。阿托伐醌-氯胍组无早期恶性疟或间日疟病例,但50.0%发生晚期间日疟,与甲氟喹(46.5%)和多西环素(43.5%)相近;伯氨喹组仅2例(1.4%)晚期疟疾(P < .0001)。

要点

  • 阿托伐醌-氯胍对间日疟提供因果性(肝期裂殖体)预防,但对晚期休眠子复发无效。
  • 阿托伐醌-氯胍使用者中50.0%发生晚期间日疟,甲氟喹46.5%,多西环素43.5%。
  • 伯氨喹使用者仅2例(1.4%)发生晚期疟疾,作者建议在恶性疟与间日疟高共流行区考虑伯氨喹为首选化学预防药。

核心结论

  • 短程阿托伐醌-氯胍似乎对间日疟提供因果性(肝期裂殖体)预防,但对晚期、休眠子再激活相关的发作无效。
  • 作者认为,在恶性疟与间日疟高共流行区,伯氨喹应被考虑为首选化学预防药。

研究设计与样本

  • 回顾性观察研究,随访11年,纳入曾赴埃塞俄比亚奥莫河高疟区的以色列漂流者252名,返回后随访至少1年。
  • 预防用药包括甲氟喹、多西环素、伯氨喹和阿托伐醌-氯胍;预防失败分为暴露后1个月内的早期疟疾和晚期疟疾。

主要发现

  • 252名旅行者中62名(24.6%)发生疟疾,其中56例(91.9%)由间日疟原虫引起,54例(87.1%)为晚期疟疾。
  • 阿托伐醌-氯胍使用者中无早期恶性疟或间日疟病例,但50.0%发生晚期间日疟;甲氟喹使用者46.5%、多西环素使用者43.5%发生晚期间日疟;伯氨喹使用者仅2例(1.4%)发生晚期疟疾(P < .0001)。

关键数值与推荐

  • 阿托伐醌-氯胍使用者晚期间日疟发生率为50.0%,甲氟喹使用者为46.5%,多西环素使用者为43.5%,伯氨喹使用者为1.4%(2例),组间比较P < .0001。
  • 阿托伐醌-氯胍使用者中无早期恶性疟或间日疟病例。

临床怎么用

  • 作者认为,在恶性疟与间日疟高共流行区,伯氨喹应被考虑为化学预防的首选药物。
  • 阿托伐醌-氯胍似乎提供间日疟因果性预防,但对晚期休眠子再激活相关发作无效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atovaquone-proguanil is considered causal prophylaxis (inhibition of liver-stage schizonts) for Plasmodium falciparum; however, its causal prophylactic efficacy for Plasmodium vivax is not known. Travelers returning to nonendemic areas provide a unique opportunity to study P. vivax prophylaxis. METHODS: In a retrospective observational study, for 11 years, Israeli rafters who had traveled to the Omo River in Ethiopia, a highly malaria-endemic area, were followed for at least 1 year after their return. Malaria prophylaxis used during this period included mefloquine, doxycycline, primaquine, and atovaquone-proguanil. Prophylaxis failure was divided into early (within a month of exposure) and late malaria. RESULTS: Two hundred fifty-two travelers were included in the study. Sixty-two (24.6%) travelers developed malaria, 56 (91.9%) caused by P. vivax, with 54 (87.1%) cases considered as late malaria. Among travelers using atovaquone-proguanil, there were no cases of early P. falciparum or P. vivax malaria. However, 50.0% of atovaquone-proguanil users developed late vivax malaria, as did 46.5% and 43.5% of mefloquine and doxycycline users, respectively; only 2 (1.4%) primaquine users developed late malaria (P < .0001). CONCLUSIONS: Short-course atovaquone-proguanil appears to provide causal (liver schizont stage) prophylaxis for P. vivax, but is ineffective against late, hypnozoite reactivation-related attacks. These findings suggest that primaquine should be considered as the chemoprophylactic agent of choice for areas with high co-circulation of P. falciparum and P. vivax.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Meltzer E, Rahav G, Schwartz E, et al. Vivax Malaria Chemoprophylaxis: The Role of Atovaquone-Proguanil Compared to Other Options. Clin Infect Dis. 2018. PMID: 29228132. doi:10.1093/cid/cix1077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。